Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
Stocks · News reference
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
October 1, 2026 records indicate that Representative David Taylor filed a purchase of Amgen (NASDAQ:AMGN), valued between $3,003 and $45,000. According to the October filing, the transaction occurred on September 22,
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.
Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight
The coronary artery disease treatment landscape is rapidly evolving with 20+ pharmaceutical companies actively developing 22+ pipeline drugs. Key players including Roche, Verve Therapeutics, Amgen, and others are advancing therapies targeting residual cardiovascular risk through novel mechanisms such as Factor XI inhibitors, gene therapy, and anti-inflammatory approaches. Recent clinical trial progress includes positive Phase IIa results for vortosiran and Phase II initiation of SRSD107, signaling growing momentum in addressing high-risk CAD patients beyond conventional treatments.
Cathie Wood Bets Big on Flying Taxis With Joby, Archer Trades—Invests in TSLA Robotaxi Rivals WeRide, Pony AI
ARK Invest buys millions in Joby and Archer eVTOL shares, while also investing in robotaxi firms like WeRide.
Axios Reported Earlier Sunday, Nvidia-Backed Reflection Prepares Powerful Open-Weight AI System To Challenge Chinese Upstarts, U.S. AI Giants
https://www.axios.com/2026/10/04/reflection-open-weight-ai